Bladder Small Cell Neuroendocrine Carcinoma Recruiting Phase 1 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0113275 (Bladder Small Cell Neuroendocrine Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsTreatment